The Emerging Role of Electronic Medical Records in Pharmacogenomics

Health‐care information technology and genotyping technology are both advancing rapidly, creating new opportunities for medical and scientific discovery. The convergence of these two technologies is now facilitating genetic association studies of unprecedented size within the context of routine clinical care. As a result, the medical community will soon be presented with a number of novel opportunities to bring functional genomics to the bedside in the area of pharmacotherapy. By linking biological material to comprehensive medical records, large multi‐institutional biobanks are now poised to advance the field of pharmacogenomics through three distinct mechanisms: (i) retrospective assessment of previously known findings in a clinical practice‐based setting, (ii) discovery of new associations in huge observational cohorts, and (iii) prospective application in a setting capable of providing real‐time decision support. This review explores each of these translational mechanisms within a historical framework.

[1]  C. McDonald.  Protocol-based computer reminders, the quality of care and the non-perfectability of man. , 1976, The New England journal of medicine.

[2]  C J McDonald,et al.  A computer-based record and clinical monitoring system for ambulatory care. , 1977, American journal of public health.

[3]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[4]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[5]  Carol Friedman,et al.  A broad-coverage natural language processing system , 2000, AMIA.

[6]  R. Subramanian,et al.  Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[7]  Donald S. Gardner,et al.  Using genomics to help predict drug interactions , 2004, J. Biomed. Informatics.

[8]  T. Strandberg,et al.  Lipid-lowering response to statins is affected by CYP3A5 polymorphism. , 2004, Pharmacogenetics.

[9]  Russell A Wilke,et al.  Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage , 2005, Pharmacogenetics and genomics.

[10]  The HMO Research Network , 2005 .

[11]  David M. Reif,et al.  Combinatorial Pharmacogenetics , 2005, Nature Reviews Drug Discovery.

[12]  C. McCarty,et al.  Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. , 2005, Personalized medicine.

[13]  Russell A. Wilke,et al.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2007, Nature Reviews Drug Discovery.

[14]  J. Hokanson,et al.  Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. , 2007, Journal of clinical epidemiology.

[15]  Geoff Gordon,et al.  Use of natural language programming to extract medication from unstructured electronic medical records. , 2007, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[16]  D. Mrazek,et al.  Cytochrome P450 2D6 genotype variation and venlafaxine dosage. , 2007, Mayo Clinic proceedings.

[17]  W. Newman,et al.  Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. , 2007, Pharmacogenomics.

[18]  Kenneth D. Mandl,et al.  The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction , 2007, PloS one.

[19]  Joyce A. Mitchell,et al.  Status of clinical gene sequencing data reporting and associated risks for information loss , 2007, J. Biomed. Informatics.

[20]  Serguei V. S. Pakhomov,et al.  Quality Performance Measurement Using the Text of Electronic Medical Records , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  Chengfeng Zhao,et al.  Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository. , 2008, Basic & clinical pharmacology & toxicology.

[22]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[23]  Deborah A Nickerson,et al.  Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment , 2008, Circulation.

[24]  Sowmya R. Rao,et al.  Electronic health records in ambulatory care--a national survey of physicians. , 2008, The New England journal of medicine.

[25]  C. McCarty,et al.  Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy , 2009, Breast Cancer Research and Treatment.

[26]  Bruce M Psaty,et al.  Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. , 2008, JAMA.

[27]  John F. Hurdle,et al.  Extracting Information from Textual Documents in the Electronic Health Record: A Review of Recent Research , 2008, Yearbook of Medical Informatics.

[28]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[29]  Terrie Kitchner,et al.  Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. , 2009, Preventive cardiology.

[30]  R. Epstein,et al.  Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Wendy A. Wolf,et al.  Assessing the understanding of biobank participants , 2009, American journal of medical genetics. Part A.

[32]  Janice D Nunnelee,et al.  Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64. , 2009, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.

[33]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[34]  Sowmya R. Rao,et al.  Use of electronic health records in U.S. hospitals. , 2009, The New England journal of medicine.

[35]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[36]  Reply to V. Arena et al , 2009 .

[37]  Vasudevan Jagannathan,et al.  Assessment of commercial NLP engines for medication information extraction from dictated clinical notes , 2009, Int. J. Medical Informatics.

[38]  Randolph A. Miller,et al.  Identifying QT prolongation from ECG impressions using a general-purpose Natural Language Processor , 2009, Int. J. Medical Informatics.

[39]  R. Lifton.  Individual genomes on the horizon. , 2010, The New England journal of medicine.

[40]  Hein Putter,et al.  Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M Schwab,et al.  UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo , 2010, Clinical pharmacology and therapeutics.

[42]  Peter C Austin,et al.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study , 2010, BMJ : British Medical Journal.

[43]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[44]  Melissa A. Basford,et al.  Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. , 2010, American journal of human genetics.

[45]  George Hripcsak,et al.  Accelerating the use of electronic health records in physician practices. , 2010, The New England journal of medicine.

[46]  Paul T. Williams,et al.  Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations , 2010, PloS one.

[47]  I. Kohane,et al.  Electronic medical records for discovery research in rheumatoid arthritis , 2010, Arthritis care & research.

[48]  B. Malin,et al.  Anonymization of electronic medical records for validating genome-wide association studies , 2010, Proceedings of the National Academy of Sciences.

[49]  Son Doan,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..

[50]  K. Lunetta,et al.  Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen , 2010, Acta oncologica.

[51]  F. Lau,et al.  Use of Information Technology in Medication Reconciliation: A Scoping Review , 2010, The Annals of pharmacotherapy.

[52]  Russell A Wilke,et al.  Biobanking and pharmacogenomics. , 2010, Pharmacogenomics.